Epidemiology and economic burden of amyotrophic lateral sclerosis in the United States: a literature review

References

• Bardhan N, Tadwalkar S. Amyotrophic lateral sclerosis. Clarivate Research Reports; 2021.
   Google Scholar
• Paganoni S, Macklin EA, Hendrix S, Berry JD, Elliott MA, Maiser S, et al. Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis. N Engl J Med. 2020;383:919–30.
   PubMed Web of Science ®Google Scholar
• Cruz MP. Edaravone (Radicava): a novel neuroprotective agent for the treatment of Amyotrophic Lateral Sclerosis. P T. 2018;43:25–8.
   PubMedGoogle Scholar
• Miller RG, Mitchell JD, Lyon M, Moore DH. Riluzole for Amyotrophic Lateral Sclerosis (ALS)/Motor Neuron Disease (MND). Amyotroph Lateral Scler Other Motor Neuron Disord. 2003;4:191–206.
   PubMed Web of Science ®Google Scholar
• Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V, Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. amyotrophic lateral sclerosis/riluzole study group II. The Lancet. 1996;347:1425–31.
   PubMed Web of Science ®Google Scholar
• Achtert K, Kerkemeyer L. The economic burden of amyotrophic lateral sclerosis: a systematic eeview. Eur J Health Econ. 2021;22:1151–66.
   PubMed Web of Science ®Google Scholar
• Larkindale J, Yang W, Hogan PF, Simon CJ, Zhang Y, Jain A, et al. Cost of illness for neuromuscular diseases in the United States. Muscle Nerve. 2014;49:431–8.
   PubMed Web of Science ®Google Scholar
• Moore A, Young CA, Hughes DA. Health utilities and costs for motor neurone disease. Value Health. 2019;22:1257–65.
   PubMed Web of Science ®Google Scholar
• Muscular Dystrophy Association [MDA]. Cost of amyotrophic lateral sclerosis, muscular dystrophy, and spinal muscular atrophy in the United States. Muscular Dystrophy Association, The Lewin Group Inc. 2012.
   Google Scholar
• Institute for Clinical and Economic Review (ICER). ICER publishes evidence report on treatments for amyotrophic lateral sclerosis 2022. https://icer.org/news-insights/press-releases/icer-publishes-evidence-report-on-treatments-for-amyotrophic-lateral-sclerosis/
   Google Scholar
• Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
   PubMed Web of Science ®Google Scholar
• Gladman M, Zinman L. The economic impact of amyotrophic lateral sclerosis: a systematic review. Expert Rev Pharmacoecon Outcomes Res. 2015;15:439–50.
   PubMed Web of Science ®Google Scholar
• XE Currency Converter. XE foreign currency converter. https://www.xe.com/currencyconverter/
   Google Scholar
• Kmet LM, Cook LS, Lee RC. Standard quality assessment criteria for evaluating primary research papers from a variety of fields. Edmonton: Alberta Heritage Foundation for Medical Research; 2004.
   Google Scholar
• Bhattacharya R, Harvey RA, Abraham K, Rosen J, Mehta P. Amyotrophic lateral sclerosis among patients with a medicare advantage prescription drug plan; prevalence, survival and patient characteristics. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:251–9.
   PubMed Web of Science ®Google Scholar
• L'Italien GJ, Qureshi IA, Clark B, Simmons Z. Determinants of mortality among hospitalized patients with amyotrophic lateral sclerosis - results from the 2016 national inpatient sample. Neurology 2019;92(15): P4.4–017.
   Web of Science ®Google Scholar
• Larson TC, Kaye W, Mehta P, Horton DK. Amyotrophic lateral sclerosis mortality in the United States, 2011-2014. Neuroepidemiology 2018;51:96–103.
   PubMed Web of Science ®Google Scholar
• Mehta P, Kaye W, Raymond J, Punjani R, Larson T, Cohen J, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2015. MMWR Morb Mortal Wkly Rep. 2018;67:1285–9.
   PubMed Web of Science ®Google Scholar
• Mehta P, Kaye W, Raymond J, Wu R, Larson T, Punjani R, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2014. MMWR Morb Mortal Wkly Rep. 2018;67:216–8.
   PubMed Web of Science ®Google Scholar
• Mehta P, Kaye W, Bryan L, Larson T, Copeland T, Wu J, et al. Prevalence of amyotrophic lateral sclerosis - United States, 2012-2013. MMWR Surveill Summ. 2016;65:1–12.
   PubMed Web of Science ®Google Scholar
• Punjani R, Wagner L, Horton K, Kaye W. Atlanta metropolitan area amyotrophic lateral sclerosis (ALS) surveillance: incidence and prevalence 2009-2011 and survival characteristics through 2015. Amyotroph Lateral Scler Frontotemporal Degener. 2020;21:123–30.
   PubMed Web of Science ®Google Scholar
• Roberts AL, Johnson NJ, Chen JT, Cudkowicz ME, Weisskopf MG. Race/ethnicity, socioeconomic status, and ALS mortality in the United States. Neurology 2016;87:2300–8.
   PubMed Web of Science ®Google Scholar
• Sagiraju HKR, Zivkovic S, VanCott AC, Patwa H, Gimeno Ruiz de Porras D, Amuan ME, et al. Amyotrophic lateral sclerosis among veterans deployed in support of post-9/11 U.S. conflicts. Mil Med. 2020;185:e501–e509.
   PubMed Web of Science ®Google Scholar
• Wagner L, Rechtman L, Jordan H, Ritsick M, Sanchez M, Sorenson E, et al. State and metropolitan area-based Amyotrophic Lateral Sclerosis (ALS) surveillance. Amyotroph Lateral Scler Frontotemporal Degener. 2015;17:128–34.
   PubMed Web of Science ®Google Scholar
• Thakore NJ, Pioro EP, Udeh BL, Lapin BR, Katzan IL. A cost-effectiveness framework for amyotrophic lateral sclerosis, applied to riluzole. Value Health. 2020;23:1543–51.
   PubMed Web of Science ®Google Scholar
• Meng L, Bian A, Jordan S, Wolff A, Shefner JM, Andrews J. Profile of medical care costs in patients with amyotrophic lateral sclerosis in the medicare programme and under commercial insurance. Amyotroph Lateral Scler Frontotemporal Degener. 2018;19:134–42.
   PubMed Web of Science ®Google Scholar
• Elman LB, Stanley L, Gibbons P, McCluskey L. A cost comparison of hospice care in amyotrophic lateral sclerosis and lung cancer. Am J Hosp Palliat Care. 2006;23:212–6.
   PubMedGoogle Scholar
• Paganoni S, van de Rijn M, Drake K, Burke K, Doyle M, Ellrodt AS, et al. Adjusted cost analysis of video televisits for the care of people with amyotrophic lateral sclerosis. Muscle Nerve. 2019;60:147–54.
   PubMed Web of Science ®Google Scholar
• Millard J, Raza SA, Boller E, Bauer E, Sullivan J, Apple S. PND125 real-world healthcare utilization, costs, and progression milestone patterns among ffs medicare patients newly diagnoses with amyotrophic lateral sclerosis. Value in Health. 2020;23:S283.
   Web of Science ®Google Scholar
• Cohen B, Balcells C, Hotchkiss B, Aggarwal K, Karaa A. A retrospective analysis of health care utilization for patients with mitochondrial disease in the United States: 2008–2015. Orphanet J Rare Dis. 2018;13:210.
   PubMed Web of Science ®Google Scholar
• Jalali-Sohi A, Darki L, Phan L, Beydoun S. A two-year retrospective chart review to evaluate demographics of amyotrophic lateral sclerosis patients attending a multidisciplinary clinic (5523). Neurology 2020;94:5523.
   Web of Science ®Google Scholar
• United States Census Bureau. Quick Facts, United States. https://www.census.gov/quickfacts/fact/table/US/POP010220
   Google Scholar
• Chio A, Mora G, Moglia C, Manera U, Canosa A, Cammarosano S, Piemonte and Valle d’Aosta Register for ALS (PARALS), et al. Secular trends of amyotrophic lateral sclerosis: the piemonte and Valle d‘Aosta Register. JAMA Neurol. 2017;74:1097–104.
   PubMed Web of Science ®Google Scholar
• Logroscino G, Piccininni M. Amyotrophic lateral sclerosis descriptive epidemiology: the origin of geographic difference. Neuroepidemiology 2019;52:93–103.
   PubMed Web of Science ®Google Scholar
• Palese F, Sartori A, Verriello L, Ros S, Passadore P, Manganotti P, et al. Epidemiology of amyotrophic lateral sclerosis in friuli-venezia giulia, North-Eastern Italy, 2002-2014: a retrospective population-based study. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20:90–9.
   PubMed Web of Science ®Google Scholar
• Longinetti E, Fang F. Epidemiology of amyotrophic lateral sclerosis: an update of recent literature. Curr Opin Neurol. 2019;32:771–6.
   PubMed Web of Science ®Google Scholar
• Mehta P, Raymond J, Punjani R, Han M, Larson T, Kaye W, et al. Prevalence of amyotrophic lateral sclerosis in the United States Using Established and Novel Methodologies, 2017. Amyotroph Lateral Sclero Frontotemporal Degener . 2022;15:1–9.
   Google Scholar
• Mehta P, Raymond J, Punjani R, Larson T, Bove F, Kaye W, et al. Prevalence of Amyotrophic Lateral Sclerosis (ALS), United States, 2016. Amyotroph Lateral Scler Frontotemporal Degener. 2022;23:220–5.
   PubMed Web of Science ®Google Scholar
• Gladman M, Dharamshi C, Zinman L. Economic burden of amyotrophic lateral sclerosis: a Canadian study of out-of-pocket expenses. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15:426–32.
   PubMed Web of Science ®Google Scholar
• Nonoyama ML, McKim DA, Guerriere D, Coyte PC, Wasilewski M, Avendano M, et al. Healthcare Utilisation and Costs of Home Mechanical Ventilation. Thorax 2018;73:644–51.
   Web of Science ®Google Scholar
• Schepelmann K, Winter Y, Spottke AE, Claus D, Grothe C, Schröder R, et al. Socioeconomic burden of amyotrophic lateral sclerosis, myasthenia gravis and facioscapulohumeral muscular dystrophy. J Neurol. 2010;257:15–23.
   PubMed Web of Science ®Google Scholar
• Lopez-Bastida J, Perestelo-Perez L, Monton-Alvarez F, Serrano-Aguilar P, Alfonso-Sanchez JL. Social Economic Costs and Health-Related Quality of Life in Patients with Amyotrophic Lateral Sclerosis in Spain. Amyotroph Lateral Scler. 2009;10:237–43.
   PubMed Web of Science ®Google Scholar
• Oh J, An JW, Oh S-I, Oh KW, Kim JA, Lee JS, et al. Socioeconomic costs of amyotrophic lateral sclerosis according to staging system. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:202–8.
   PubMed Web of Science ®Google Scholar
• Schönfelder E, Osmanovic A, Müschen LH, Petri S, Schreiber-Katz O. Costs of Illness in Amyotrophic Lateral Sclerosis (ALS): a cross-sectional survey in Germany. Orphanet J Rare Dis. 2020;15:149.
   PubMed Web of Science ®Google Scholar
• Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Eurals Consortium, et al. Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler. 2009;10:310–23.
   PubMed Web of Science ®Google Scholar
• Knibb JA, Keren N, Kulka A, Leigh PN, Martin S, Shaw CE, et al. A clinical tool for predicting survival in ALS. J Neurol Neurosurg Psychiatry. 2016;87:1361–7.
   PubMed Web of Science ®Google Scholar
• Alčaz S, Jarebinski M, Pekmezović T, Stević‐Marinković Z, Pavlović S, Apostolski S. Epidemiological and clinical vharacteristics of ALS in Belgrade, Yugoslavia. Acta Neurol Scand. 1996;94:264–8.
   PubMed Web of Science ®Google Scholar
• Orphanet. Orphanet Report Series: Prevalence of Rare Diseases: Bibliographic data. 2011. http://www.orpha.net/orphacom/cahiers/docs/GB/Prevalence_of_rare_diseases_by_alphabetical_list.pdf
   Google Scholar
• Worms PM. The epidemiology of motor neuron diseases: a review of recent studies. J Neurol Sci. 2001;191:3–9.
   PubMed Web of Science ®Google Scholar
• Orphanet. Orphanet Report Series: Prevalence of Rare Diseases: Bibliographic data. 2012.
   Google Scholar
• Wagner L, Archer NP, Williamson DM, Henry JP, Schiffer R, Jackson CE. Prevalence of amyotrophic lateral sclerosis in Texas, 1998-2003. Tex Med 2012;108:e1-e.
   Google Scholar
• Dubinsky R, Chen J, Lai, SM. Trends in hospital utilization and outcome for patients with ALS: analysis of a large U.S. cohort. Neurology. 2006;67:777–80.
   Google Scholar